278 related articles for article (PubMed ID: 8269588)
1. Preclinical activity of a new platinum analogue, lobaplatin, in cisplatin-sensitive and -resistant human testicular, ovarian, and gastric carcinoma cell lines.
Harstrick A; Bokemeyer C; Scharnofkse M; Hapke G; Reile D; Schmoll HJ
Cancer Chemother Pharmacol; 1993; 33(1):43-7. PubMed ID: 8269588
[TBL] [Abstract][Full Text] [Related]
2. Preclinical activity of lobaplatin as a single agent and in combination with taxanes for ovarian carcinoma cells.
Sun X; Lou LG; Sui DH; Wu XH
Asian Pac J Cancer Prev; 2014; 15(22):9939-43. PubMed ID: 25520132
[TBL] [Abstract][Full Text] [Related]
3. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
Kelland LR; Abel G; McKeage MJ; Jones M; Goddard PM; Valenti M; Murrer BA; Harrap KR
Cancer Res; 1993 Jun; 53(11):2581-6. PubMed ID: 8388318
[TBL] [Abstract][Full Text] [Related]
4. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds.
Meijer C; Mulder NH; Timmer-Bosscha H; Sluiter WJ; Meersma GJ; de Vries EG
Cancer Res; 1992 Dec; 52(24):6885-9. PubMed ID: 1458477
[TBL] [Abstract][Full Text] [Related]
5. Hyperthermia enhances the cytotoxicity and platinum-DNA adduct formation of lobaplatin and oxaliplatin in cultured SW 1573 cells.
Rietbroek RC; van de Vaart PJ; Haveman J; Blommaert FA; Geerdink A; Bakker PJ; Veenhof CH
J Cancer Res Clin Oncol; 1997; 123(1):6-12. PubMed ID: 8996534
[TBL] [Abstract][Full Text] [Related]
6. In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers.
Alberts DS; Fanta PT; Running KL; Adair LP; Garcia DJ; Liu-Stevens R; Salmon SE
Cancer Chemother Pharmacol; 1997; 39(6):493-7. PubMed ID: 9118460
[TBL] [Abstract][Full Text] [Related]
7. Human ovarian-carcinoma cell lines and companion xenografts: a disease-oriented approach to new platinum anticancer drug discovery.
Kelland LR; Jones M; Abel G; Valenti M; Gwynne J; Harrap KR
Cancer Chemother Pharmacol; 1992; 30(1):43-50. PubMed ID: 1586979
[TBL] [Abstract][Full Text] [Related]
8. Comparative cytotoxicity of CI-973, cisplatin, carboplatin and tetraplatin in human ovarian carcinoma cell lines.
Perez RP; O'Dwyer PJ; Handel LM; Ozols RF; Hamilton TC
Int J Cancer; 1991 May; 48(2):265-9. PubMed ID: 2019469
[TBL] [Abstract][Full Text] [Related]
9. Selective potentiation of platinum drug cytotoxicity in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines by amphotericin B.
Sharp SY; Mistry P; Valenti MR; Bryant AP; Kelland LR
Cancer Chemother Pharmacol; 1994; 35(2):137-43. PubMed ID: 7987990
[TBL] [Abstract][Full Text] [Related]
10. Drug interactions of 5-fluorouracil with either cisplatin or lobaplatin--a new, clinically active platinum analog in established human cancer cell lines.
Harstrick A; Vanhoefer U; Heidemann A; Druyen H; Wilke H; Seeber S
Anticancer Drugs; 1997 Apr; 8(4):391-5. PubMed ID: 9180394
[TBL] [Abstract][Full Text] [Related]
11. A novel trans-platinum coordination complex possessing in vitro and in vivo antitumor activity.
Kelland LR; Barnard CF; Mellish KJ; Jones M; Goddard PM; Valenti M; Bryant A; Murrer BA; Harrap KR
Cancer Res; 1994 Nov; 54(21):5618-22. PubMed ID: 7923207
[TBL] [Abstract][Full Text] [Related]
12. Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells.
O'Neill CF; Hunakova L; Kelland LR
Chem Biol Interact; 1999 Nov; 123(1):11-29. PubMed ID: 10597899
[TBL] [Abstract][Full Text] [Related]
13. In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin.
Mellish KJ; Kelland LR; Harrap KR
Br J Cancer; 1993 Aug; 68(2):240-50. PubMed ID: 8347478
[TBL] [Abstract][Full Text] [Related]
14. Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line.
Kelland LR; Mistry P; Abel G; Freidlos F; Loh SY; Roberts JJ; Harrap KR
Cancer Res; 1992 Apr; 52(7):1710-6. PubMed ID: 1312897
[TBL] [Abstract][Full Text] [Related]
15. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
O'Neill CF; Koberle B; Masters JR; Kelland LR
Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
[TBL] [Abstract][Full Text] [Related]
16. Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.
Kelland LR; Abel G
Cancer Chemother Pharmacol; 1992; 30(6):444-50. PubMed ID: 1356649
[TBL] [Abstract][Full Text] [Related]
17. Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenografts.
Jones M; Siracky J; Kelland LR; Harrap KR
Br J Cancer; 1993 Jan; 67(1):24-9. PubMed ID: 8427780
[TBL] [Abstract][Full Text] [Related]
18. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells.
Saris CP; van de Vaart PJ; Rietbroek RC; Blommaert FA
Carcinogenesis; 1996 Dec; 17(12):2763-9. PubMed ID: 9006117
[TBL] [Abstract][Full Text] [Related]
19. A trial of lobaplatin (D-19466) in platinum-resistant ovarian cancer.
Kavanagh JJ; Edwards CL; Freedman RS; Finnegan MB; Balat O; Tresukosol D; Burk K; Loechner S; Hord M; Franklin JL
Gynecol Oncol; 1995 Jul; 58(1):106-9. PubMed ID: 7789874
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues.
Behrens BC; Hamilton TC; Masuda H; Grotzinger KR; Whang-Peng J; Louie KG; Knutsen T; McKoy WM; Young RC; Ozols RF
Cancer Res; 1987 Jan; 47(2):414-8. PubMed ID: 3539322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
